EHS
EHS

Pegcetacoplan shows increased treatment benefit at 2 years


October 02, 2022

3 min watch

Source:

Wykoff CC. Treatment of geographic atrophy secondary to AMD with pegcetacoplan: Two-year outcomes from the randomized phase 3 DERBY and OAKS trials. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.

Disclosures:
Wykoff reports serving on a global clinical trial steering committee with Apellis.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Charles C. Wykoff, MD, PhD, shares data from the DERBY and OAKS trials assessing pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

“Through 2 years in the phase 3 global OAKS and DERBY program involving over 1,200 patients, we’re seeing an increasing treatment benefit that is consistent over time with pegcetacoplan, we’re seeing a fascinating microperimetry signal that is showing preservation of visual function with preservation of photoreceptor cells, and finally, we saw a manageable safety profile with an increased rate of wet AMD,” Wykoff said.



Source link

EHS
Back to top button